Salvage therapy for relapsed or refractory acute myeloid leukemia

Therapeutic Advances in Hematology

Volumn 2, Issue 2, 2011, Pages 73-82

  Mangan, James K ^a   Luger, Selina M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

acute myeloid leukemia; relapsed or refractory; salvage therapy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTHRACYCLINE; BEXAROTENE; CLOFARABINE; CYTARABINE; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; LENALIDOMIDE; LESTAURTINIB; MIDOSTAURIN; MITOXANTRONE; QUIZARTINIB; RAPAMYCIN; [4 [2 (1H INDAZOL 3 YL)VINYL]PHENYL](1 PIPERAZINYL)METHANONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADD ON THERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG MEGADOSE; HAND FOOT SYNDROME; HUMAN; HYPERTRANSAMINASEMIA; LEUKEMIA RELAPSE; OVERALL SURVIVAL; PRIORITY JOURNAL; RASH; REVIEW; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84993767805     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620711402533     Document Type: Review

References (56)

1. Archimbaud E. Thomas X. Leblond V. Michallet M. Fenaux P. Cordonnier C. et al. (1995) Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: Long-term follow-up of the etoposide, mitoxantrone and cytarabine-86 trial. J Clin Oncol 13: 11–18.
2. Armistead P.M. de Lima M. Pierce S. Qiao W. Wang X. Thall P.F. et al. (2009) Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia. Biol Blood Marrow Transplant 15: 1431–1438.
3. Becker P.S. Estey E. Petersdorf S. Storer B.E. Appelbaum F.R. (2009) G-CSF priming, clofarabine, and high-dose cytarabine (GCLAC) for relapsed or refractory acute myeloid leukemia (AML). Blood 114 abstract 2068.
4. Blum W. Klisovic R.B. Becker H. Yang X. Rozewski D.M. Phelps M.A. et al. (2010) Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol 28: 4919–4925.
5. Bolanos-Meade, J., Smith, B.D., Gore, S.D., McDevitt, M.A., Luznik, L., Fuchs, E.J. et al. (2010) 5-Azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 15 October [epub ahead of print].
6. Breems D.A. van Putten W.L. Huijgens P.C. Ossenkoppele G.J. Verhoef G.E. Verdonck L.F. et al. (2005) Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 23: 1969–1978.
7. Cortes J. Foran J. Ghirdaladze D. de Vetten M.P. Zodelava M. Holman P. et al. (2009) AC220, a potent, selective, second generation FLT 3 receptor tyrosine kinase (RTK) inhibitor, in a First-in-Human (FIH) Phase 1 AML study. Blood 114: abstract 636–abstract 646.
8. Craddock C. Tauro S. Moss P. Grimwade D. (2005) Biology and management of relapsed acute myeloid leukemia. Br J Haematol 129: 18–34.
9. Crump M. Hedley D. Kamel-Reid S. Leber B. Wells R. Brandwein J. et al. (2010) A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: A NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leuk Lymphoma 51: 252–260.
10. Denz U. Bertz H. Ihorst G. Wasch R. Finke J. (2010) Improved outcome in relapsed and refractory myeloid malignancies for unrelated versus related donor allogeneic peripheral blood-derived hematopoietic cell transplantation. Bone Marrow Trans 45: 1309–1315.
11. Duval M. Klein J.P. He W. Cahn J.Y. Cairo M. Camitta B.M. et al. (2010) Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 28: 3730–3738.
12. Estey E.H. (2000) Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia 14: 476–479.
13. Estey E. Plunkett W. Gandhi V. Rios M.B. Kantarjian H. Keating M.J. (1993) Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myeloid leukemia. Leuk Lymphoma 9: 343–350.
14. Faderl S. Ferrajoli A. Wierda W. Huang X. Verstovsek S. Ravandi F. et al. (2008) Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer 113: 2090–2096.
15. Fehniger, T.A., Uy, G.L., Trinkaus, K., Nelson, A.D., Demland, J., Abboud, C.N. et al. (2010) A phase II study of high dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood [epub ahead of print].
16. Ferrara F. Mellillo L. Montillo M. Leoni F. Pinto A. Mele G. et al. (1999) Fludarabine, cytarabine, and G-CSF for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation. Ann Hematol 78: 380–384.
17. Fischer T. Stone R.M. de Angelo D.J. Galinsky I. Estey E. Lanza C. et al. (2010) Phase IIb trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 28: 4339–4345.
18. Garcia-Manero G. Yang A.S. Klimek V. Cortes J. Ravandi F. Newsome W.M. et al. (2007) Phase I / II study of MGDC0103, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-Azacitidine in higher-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Blood 110: abstract 444–abstract 454.
19. Giles F. Verstovsek S. Garcia-Manero G. Thomas D. Ravandi F. Wierda W. et al. (2006) Validation of the European Prognostic Index for young adult patients with acute myeloid leukemia in first relapse. Br J Haematol 134: 58–60.
20. Herzig R.H. Lazarus H.M. Wolff S.N. Phillips G.L. Herzig G.P. (1985) High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. J Clin Oncol 3: 992–997.
21. Ho A.D. Lipp T. Ehninger G. Illiger H.J. Meyer P. Freund M. et al. (1988) Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia – an active and well-tolerated regimen. J Clin Oncol 6: 213–217.
22. Horowitz M.M. Rowlings P.A. (1997) An update from the International Bone Marrow Transplant Registry and the Autologous Blood and Bone Marrow Transplant Registry on current activity in hematopoietic stem cell transplantation. Curr Opin Hematol 4: 395–400.
23. Itzykson R. Thepot S. Recher C. Delaunay J. Quesnel B. Dreyfus F. et al. (2009) Azacytidine in refractory or relapsed AML after intensive chemotherapy (IC): Results of the French ATU Program. Blood 114: abstract 1054–abstract 1154.
24. Kantarjian H. Gandhi V. Cortes J. Verstoversusek S. Du M. Garcia-Manero G. et al. (2003) Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 102: 2379–2386.
25. Keating M.J. Kantarjian H. Smith T.L. Estey E. Walters R. Andersson B. et al. (1989) Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 7: 1071–1080.
26. Kern W. Aul C. Maschmeyer G. Schonrock-Nabulsi R. Ludwig W.D. Bartholomaus A. et al. (1998) Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison. Leukemia 12: 1049–1055.
27. Kotla V. Goel S. Nischal S. Heuck C. Vivek K. Das B. et al. (2009) Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2: 36–46.
28. Leopold L.H. Willemze R. (2002) The treatment of acute myeloid leukemia in first relapse: A comprehensive review of the literature. Leuk Lymphoma 43: 1715–1727.
29. Levis M. Ravandi F. Wang E.S. Baer M.R. Perl A. Coutre S. et al. (2009) Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for FLT 3 mutant AML patients in first relapse. Blood 114: abstract 788–abstract 798.
30. Litzow M.R. Othus M. Cripe L.D. Gore S.D. Lazarus H.M. Lee S.J. et al. (2010) Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukemia: a report from the Eastern Cooperative Oncology Group. Br J Haematol 148: 217–225.
31. Locke, F.L., Artz, A., Rich, E., Zhang, Y., van Besien, K. and Stock, W. (2010) Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML. Bone Marrow Transplant [epub ahead of print].
32. Martin M.G. Augustin K.M. Uy G.L. Welch J.S. Hladnik L. Goyal S. et al. (2009) Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF. Am J Hematol 84: 733–737.
33. Metzelder S. Scholl S. Kroger M. Reiter A. Meyer R.G. Heinecke T. et al. (2009 a) Compassionate use of sorafenib in relapsed and refractory FLT3-ITD positive acute myeloid leukemia. Blood 114: abstract 2060–abstract 2070.
34. Metzelder S. Wang Y. Wollmer E. Wanzel M. Teichler S. Chaturvedi A. et al. (2009 b) Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: Sustained regression before and after allogeneic stem cell transplantation. Blood 113: 6567–6571.
35. Ohno R. Naoe T. Kanamaru A. Yoshida M. Hiraoka A. Kobayashi T. et al. (1994) A double-blind controlled study of granulocyte-colony stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group. Blood 83: 2086–2092.
36. Pagano L. Fianchi L. Caira M. Rutella S. Leone G. (2007) The role of gemtuzumab ozagamicin in the treatment of acute myeloid leukemia. Oncogene 26: 3679–3690.
37. Pastore D. Specchia G. Carluccio P. Liso A. Mestice A. Rizzi R. et al. (2003) FLAG-IDA in the treatment of refractory / relapsed acute myeloid leukemia: Single-center experience. Ann Hematol 82: 231–235.
38. Perl A.E. Kasner M.T. Tsai D.E. Vogl D.T. Loren A.W. Schuster S.J. et al. (2009) A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myeloid leukemia. Clinc Cancer Res 15: 6732–6739.
39. Pratz K.W. Cortes J. Roboz G. Rao N. Arowojolu O. Stine A. et al. (2008) A pharmacodynamic study of the Flt 3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood 113: 3938–3946.
40. Ravandi F. Kantarjian H. Faderl S. Garcia-Manero G. O'Brien S. Koller C. et al. (2010) Outcome of patients with FLT 3 mutated acute myeloid leukemia in first relapse. Leuk Res 34: 752–756.
41. Ritchie E.K. Arnason J. Feldman E. Gergis US Mayer S.A. Ippoliti C. et al. (2009) Decitabine-based salvage therapy in adults with acute myeloid leukemia. Blood 114: abstract 2063–abstract 2073.
42. Rowe J.M. Kim H.T. Cassileth P.A. Lazarus H.M. Litzow M.R. Wiernik P.H. et al. (2010) Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have similar prognosis: A report on 1980 patients registered to 6 studies conducted by the Easter Cooperative Oncology Group. Cancer 116: 5012–5021.
43. Schroeder T. Saure C. Bruns I. Zohren F. Czibere A.G. Safaian N.N. et al. (2009) Clinical efficacy of sorafenib in patients with acute myeloid leukemia and activating FLT3-mutations. Blood 114: abstract 2057–abstract 2067.
44. Schmid C. Schleuning M. Schwerdtfeger R. Hertenstein B. Mischak-Weissinger E. Bunjes D. et al. (2006) Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 108: 1092–1099.
45. Sierra J. Storer B. Hansen J.A. Martin P.J. Petersdorf E.W. Woolfrey A. et al. (2000) Unrelated donor marrow transplantation for acute myeloid leukemia: An update of the Seattle experience. Bone Marrow Transplant 26: 397–404.
46. Sievers E.L. Appelbaum F.R. Spielberger R.T. Forman S.J. Flowers D. Smith F.O. et al. (1999) Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93: 3678–3684.
47. Silverman L.R. Verma A. Odchimar-Reissig R. Le Blanc A. Najfeld V. Gabrilove J. et al. (2008) A phase I trial of the epigenetic modulators vorinostat, in combination with azacitidine (azaC) in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): A study of the New York Cancer Consortium. Blood 112: abstract 3656–abstract 3666.
48. Small D. (2006) Flt 3 mutations: Biology and treatment. Am Soc Hematol Educ Program 178–184.
49. Spadea A. Petti M.C. Fazi P. Vegna M.L. Arcese W. Avvisati G. et al. (1993) Mitoxantrone, etoposide, and intermediate-dose Ara-C (MEC): An effective regimen for poor risk acute myeloid leukemia. Leukemia 7: 549–552.
50. Thomas X. Fenaux P. Dombret H. Delair S. Dreyfus F. Tilly H. et al. (1999) Granulocyte–macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone, and cytarabine (EMA) in previously treated acute myeloid leukemia: A multicenter randomized placebo-controlled trial (EMA91 trial). Leukemia 13: 1214–1220.
51. Tsai D.E. Luger S.M. Andreadis C. Vogl D.T. Kemner A. Potuzak M. et al. (2008) A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia. Clin Cancer Res 14: 5619–5625.
52. Vogler W.R. McCarley D.L. Stagg M. Bartolucci A.A. Moore J. Martelo O. et al. (1994) A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial. Leukemia 8: 1847–1853.
53. Wiernik P.H. (2010) FLT 3 inhibitors for the treatment of acute myeloid leukemia. Clin Adv Hematol Oncol 8: 429–436.
54. Xu G. Thompson J.E. Carroll M. (2005) mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood 106: 4261–4268.
55. Yanada M. Garcia-Manero G. Borthakur G. Ravandi F. Kantarjian H. Estey E. (2007) Potential cure of acute myeloid leukemia. Cancer 110: 2756–2760.
56. Zhu X. Ma Y. Liu D. (2010) Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights. J Hematol Oncol 3: 17–27.